Latest News

Norgine to acquire Merus

Norgine HQ in Amsterdam, The Netherlands, © Norgine


by tg

Dutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash.

The transaction of US$342m will be financed through a combination of available cash and new credit facilities that Norgine has secured prior to the agreement. The transaction price of US$1.65 per share represents a premium of 63.4% to the closing price of US$1.01 on the TSX on May 10, 2017 and a premium of 55.1% over the 30-day volume weighted average price of $1.06 on the TSX.  

In 2016, Norgine’s total sales revenue was €295 million. The company is specialised in gastroenterology, hepatology, cancer and supportive  

Rothschild & Co. was acting as financial advisor and Torys LLP was acting as legal counsel to Merus. RBC Capital Markets is acting as financial advisor and Stikeman Elliott LLP is acting as legal counsel to Norgine.   

Novel strategy targets chronic liver diseases

The approach published in Nature Cancer leads to a cell-toxic accumulation of saturated fatty acids that drives tumour cells into apoptosis. HCC...

EU life science PPPs face less budget in Horizon Europe

The EU’s Public-Private Partnerships (PPPs), which have been under fire by the European Parliament and were renamed into ‘European Partnerships‘, are...

CAC builds biofuel plant for OMV

CAC has been assigned by OMV with overall responsibility for the construction of a biofuel plant in which biogenic input materials are processed...

French biotech investors launch spin-out alliance

Argobio SAS has been kicked off with €50m of committed capital from Kurma Partners, and the state bank Bpifrance. Co-investors include Angelini...

Next-gen COVID-19 vaccine good in preclinical tests

In contrast to injectable vaccines, the nasal jab seems capablet to induce mucosal immunity which is crucial to eliminate the virus instead only...

LSP leads €21m round into Neurent Medical

Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...

Valneva in talks with EU about 60 million vaccine doses

VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...